Relmada Therapeutics, Inc. RLMD Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$19.05M+4.1% | -$19.87M-96.9% | -$10.09M-2.3% | -$9.87M+43.8% | -$17.56M+5.9% | ||
| $956.19K-59.7% | $2.37M-34.3% | $3.61M-17.1% | $4.35M+21.9% | $3.57M-46.9% | ||
| -$15.07M-3.2% | -$14.6M-117% | -$6.72M-5.0% | -$6.4M+64.6% | -$18.07M-105% | ||
| -$135.23M-75.8% | -$76.93M-1,239% | $6.75M+1.1% | $6.68M-56.5% | $15.36M+35.4% | ||
| $3.36M— | —— | —— | —— | —— | ||
| $156.57M+67.2% | $93.64M— | —— | —— | —— | ||
| $6.28M— | —— | —— | —— | -$2.71M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Relmada Therapeutics, Inc. generate?
- Relmada Therapeutics, Inc. (RLMD) generated -$42.8M in operating cash flow over the trailing twelve months.
- What is Relmada Therapeutics, Inc.'s free cash flow?
- After $182.1M of capital expenditures, Relmada Therapeutics, Inc.'s free cash flow was -$209.9M over the trailing twelve months, down 116.5% year over year.
- Where does Relmada Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Relmada Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.